GHRS · GH Research PLC
Market Cap
$1.45B
Shares
68.64M
Volume · Oct 9
146.06K
Avg daily vol (3M)
297.52K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.45
Open$20.94
Day$19.87–21.07
52W close$12.49–30.64
Avg vol 30d267K
Short int1.8M · 2.6% float · 5.0d
Short vol61%
DataJun 2021–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$48.26M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.2%
Year over year · more shares
Price change (1Y)
+60.9%
Trailing year
Short interest
2.6%
Latest settlement · 5.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−25%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
+12%
trailing
YTD return
+61%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
1 of 64 funds reported for Sep 30 · net +9.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.57% of float · ▼ -34.8% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 3-yr high, broad support
Squeeze score
39
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−25%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $27 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
1 of 64 funds reported for Sep 30 · net +9.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.57% of float · ▼ -34.8% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $20 · 44%
Range high $31
vs 200-day avg -3%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GHRS
this stock
GH Research PLC
|
$1.45B | +61.0% | — | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GHRS | -10.5% | -25.0% | +11.5% | -12.9% | +61.0% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -11.8% | -27.2% | +2.5% | -14.4% | +47.5% |